SNGX
Soligenix, Inc.
Biotechnology
Market Cap$3M
5Y Perf.-99.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SNGX vs XTLB
Revenue, margins, valuation, and 5-year total return — side by side.
XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$358K
5Y Perf.-39.4%
SNGX vs XTLB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SNGX | XTLB |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $3M | $358K |
| Revenue (TTM) | $0.00 | $451K |
| Net Income (TTM) | $-11M | $-1M |
| Gross Margin | — | 26.4% |
| Operating Margin | — | -481.6% |
| Total Debt | $1M | $138K |
| Cash & Equiv. | $8M | $371K |
SNGX vs XTLB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SNGX
XTLB
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Soligenix, Inc. (SNGX) | 100 | 0.1 | -99.9% |
| XTL Biopharmaceutic… (XTLB) | 100 | 60.6 | -39.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SNGX vs XTLB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: XTLB leads in 3 of 6 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. Soligenix, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
SNGX
Soligenix, Inc.
The Growth Play
SNGX is the clearest fit if your priority is growth exposure.
- Rev growth -100.0%, EPS growth 60.7%
- -100.0% revenue growth vs XTLB's -173.2%
- 2.4% margin vs XTLB's -227.7%
Best for: growth exposure
XTLB
XTL Biopharmaceuticals Ltd.
The Income Pick
XTLB carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.71
- -84.5% 10Y total return vs SNGX's -100.0%
- Lower volatility, beta 1.71, Low D/E 2.5%, current ratio 0.61x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SNGX | -100.0% revenue growth vs XTLB's -173.2% |
| Quality / Margins | SNGX | 2.4% margin vs XTLB's -227.7% |
| Stability / Safety | XTLB | Beta 1.71 vs SNGX's 1.97, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | XTLB | -43.6% vs SNGX's -82.5% |
| Efficiency (ROA) | XTLB | -17.7% ROA vs SNGX's -135.7% |
SNGX vs XTLB — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
SNGX vs XTLB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLXTLBLAGGINGSNGX
SNGXSoligenix, Inc.
1leads
XTLBXTL Biopharmaceutical…
4leads
6 Total Categories
CATEGORYLEADERvs SNGXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SNGX1/1
Valuation MetricsMultiples, price ratios, and targets
XTLB2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
XTLB6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
XTLB6/6
Risk & VolatilityBeta, volatility, and downside exposure
XTLB2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SNGX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
XTLB and SNGX operate at a comparable scale, with $451,000 and $0 in trailing revenue.
| Metric | SNGXSoligenix, Inc. | XTLBXTL Biopharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $451,000 |
| EBITDAEarnings before interest/tax | -$12M | -$1M |
| Net IncomeAfter-tax profit | -$11M | -$1M |
| Free Cash FlowCash after capex | -$10M | $0 |
| Gross MarginGross profit ÷ Revenue | — | +26.4% |
| Operating MarginEBIT ÷ Revenue | — | -4.8% |
| Net MarginNet income ÷ Revenue | — | -2.3% |
| FCF MarginFCF ÷ Revenue | — | -3.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +25.6% | +20.0% |
SNGX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
XTLB leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | SNGXSoligenix, Inc. | XTLBXTL Biopharmaceut… |
|---|---|---|
| Market CapShares × price | $3M | $357,581 |
| Enterprise ValueMkt cap + debt − cash | -$3M | $124,581 |
| Trailing P/EPrice ÷ TTM EPS | -0.07x | -0.34x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 0.79x |
| Price / BookPrice ÷ Book value/share | 0.13x | 0.07x |
| Price / FCFMarket cap ÷ FCF | — | — |
XTLB leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
XTLB leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
XTLB delivers a -25.5% return on equity — every $100 of shareholder capital generates $-26 in annual profit, vs $-3 for SNGX. XTLB carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to SNGX's 0.36x. On the Piotroski fundamental quality scale (0–9), XTLB scores 3/9 vs SNGX's 2/9, reflecting mixed financial health.
| Metric | SNGXSoligenix, Inc. | XTLBXTL Biopharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -2.7% | -25.5% |
| ROA (TTM)Return on assets | -135.7% | -17.7% |
| ROICReturn on invested capital | — | -54.1% |
| ROCEReturn on capital employed | -2.4% | -50.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 |
| Debt / EquityFinancial leverage | 0.36x | 0.03x |
| Net DebtTotal debt minus cash | -$6M | -$233,000 |
| Cash & Equiv.Liquid assets | $8M | $371,000 |
| Total DebtShort + long-term debt | $1M | $138,000 |
| Interest CoverageEBIT ÷ Interest expense | — | -13.31x |
XTLB leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
XTLB leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in XTLB five years ago would be worth $2,369 today (with dividends reinvested), compared to $11 for SNGX. Over the past 12 months, XTLB leads with a -43.6% total return vs SNGX's -82.5%. The 3-year compound annual growth rate (CAGR) favors XTLB at -12.9% vs SNGX's -72.9% — a key indicator of consistent wealth creation.
| Metric | SNGXSoligenix, Inc. | XTLBXTL Biopharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -76.7% | +35.4% |
| 1-Year ReturnPast 12 months | -82.5% | -43.6% |
| 3-Year ReturnCumulative with dividends | -98.0% | -33.9% |
| 5-Year ReturnCumulative with dividends | -99.9% | -76.3% |
| 10-Year ReturnCumulative with dividends | -100.0% | -84.5% |
| CAGR (3Y)Annualised 3-year return | -72.9% | -12.9% |
XTLB leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
XTLB leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
XTLB is the less volatile stock with a 1.71 beta — it tends to amplify market swings less than SNGX's 1.97 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XTLB currently trades 31.6% from its 52-week high vs SNGX's 5.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SNGXSoligenix, Inc. | XTLBXTL Biopharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.97x | 1.71x |
| 52-Week HighHighest price in past year | $6.23 | $10.28 |
| 52-Week LowLowest price in past year | $0.31 | $1.05 |
| % of 52W HighCurrent price vs 52-week peak | +5.3% | +31.6% |
| RSI (14)Momentum oscillator 0–100 | 18.8 | 67.4 |
| Avg Volume (50D)Average daily shares traded | 711K | 2.4M |
XTLB leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | SNGXSoligenix, Inc. | XTLBXTL Biopharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
XTLB leads in 4 of 6 categories (Valuation Metrics, Profitability & Efficiency). SNGX leads in 1 (Income & Cash Flow).
Best OverallXTL Biopharmaceuticals Ltd. (XTLB)Leads 4 of 6 categories
Loading custom metrics...
SNGX vs XTLB: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — SNGX or XTLB?
Over the past 5 years, XTL Biopharmaceuticals Ltd.
(XTLB) delivered a total return of -76. 3%, compared to -99. 9% for Soligenix, Inc. (SNGX). Over 10 years, the gap is even starker: XTLB returned -84. 5% versus SNGX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — SNGX or XTLB?
By beta (market sensitivity over 5 years), XTL Biopharmaceuticals Ltd.
(XTLB) is the lower-risk stock at 1. 71β versus Soligenix, Inc. 's 1. 97β — meaning SNGX is approximately 15% more volatile than XTLB relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 36% for Soligenix, Inc. — giving it more financial flexibility in a downturn.
03Which has better profit margins — SNGX or XTLB?
Soligenix, Inc.
(SNGX) is the more profitable company, earning 0. 0% net margin versus -227. 7% for XTL Biopharmaceuticals Ltd. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SNGX leads at 0. 0% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — XTLB leads at 0. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — SNGX or XTLB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is SNGX or XTLB better for a retirement portfolio?
For long-horizon retirement investors, XTL Biopharmaceuticals Ltd.
(XTLB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Soligenix, Inc. (SNGX) carries a higher beta of 1. 97 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XTLB: -84. 5%, SNGX: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between SNGX and XTLB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.